Lixte Biotechnology Hldgs Inc Stock Price, News & Analysis

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced a registered direct offering of 2,900,000 shares of common stock at $2.00 per share, expected to close on or about April 14, 2022. The offering will generate approximately $5.8 million in gross proceeds, which will be used for working capital and the further development of its lead clinical compound, LB-100. Co-placement agents for this offering are WestPark Capital, Inc. and WallachBeth Capital, LLC. This offering is conducted under a previously filed shelf registration statement with the SEC.

LIXTE Biotechnology Holdings announced significant new data on its lead clinical compound, LB-100, presented by Professor René Bernards at the AACR Annual Meeting. LB-100, a first-in-class protein phosphatase 2A inhibitor, shows enhanced efficacy against KRAS-mutant cancers when combined with WEE1 kinase inhibitors. The research indicates that LB-100 may increase DNA damage and stress in cancer cells, potentially leading to improved chemotherapy outcomes. LIXTE's innovative approach has gained recognition, highlighting its potential market impact and the successful collaboration with leading cancer researchers.

LIXTE Biotechnology Holdings has reported promising findings indicating that immune checkpoint therapy can significantly benefit patients with ovarian clear cell carcinomas harboring PP2A activity-reducing mutations. At a recent Society of Gynecologic Oncology meeting, researchers presented data showing that patients with mutations in PPP2R1A had a median overall survival that was not reached, contrasting with a 6.4-month survival in patients without these mutations. CEO John S. Kovach emphasized that the results support the potential of LB-100 to enhance immunotherapy across various cancers.

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) will present at the MedInvest Pharmaceutical and Biotechnology Investor Conference from March 28 to April 1, 2022. The presentation, scheduled for March 31 at 12:00 PM EDT, will be led by Founder and CEO John S. Kovach, M.D., who will provide an overview of the company and an update on its lead clinical compound, LB-100, a PP2A inhibitor. This innovative drug shows promise for enhancing cancer treatment outcomes.

Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) announced a collaboration with the Netherlands Cancer Institute and Oncode Institute, leading to an initial joint patent application for the LB-100 combination therapy. This therapy aims to enhance anti-cancer effects in patients. The partnership focuses on identifying promising drugs to use with Lixte's LB-100 for treating various cancers and understanding the molecular mechanisms involved. CEO John S. Kovach emphasized the groundbreaking approach of stimulating pathways in cancer cells to make them more vulnerable to treatment.

Lixte Biotechnology Holdings (Nasdaq: LIXT) announced that its lead compound, LB-100, a protein phosphatase inhibitor, has shown promise in preclinical studies for enhancing the efficacy of immunotherapy in cancers like colorectal, triple-negative breast, and pancreatic cancer. Research indicates that LB-100 induces molecular changes that make tumors more susceptible to treatment. The company has initiated a clinical trial combining LB-100 with chemotherapy and an immune checkpoint blocker for patients with extensive stage small cell lung cancer, aiming to convert resistant tumors into responsive ones.

Lixte Biotechnology Holdings (Nasdaq: LIXT) announced that the National Cancer Institute has resumed patient enrollment for a study evaluating LB-100's ability to penetrate malignant brain tumors. This follows a suspension due to COVID-19. The study aims to enroll up to 20 patients, with an initial goal of obtaining pharmacologic data from 8. If successful, it could pave the way for larger trials examining LB-100's impact on treatment outcomes for glioblastoma, a challenging cancer to treat. CEO Dr. John S. Kovach emphasized the potential of LB-100 to enhance existing therapies.

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) will present at the Benzinga Global Small Cap Conference on October 28, 2021. CEO John S. Kovach, M.D., will discuss the lead clinical compound, LB-100, a PP2A inhibitor, and its collaboration with the Netherlands Cancer Institute and Oncode Institute. This partnership aims to identify effective drug combinations and new targets for LB-100 in cancer treatment. Pre-clinical studies led by Professor René Bernards will utilize genome-wide functional genetic techniques to enhance treatment efficacy.

Lixte Biotechnology Holdings has announced a collaboration with the Netherlands Cancer Institute and Oncode Institute to explore drug combinations with their lead compound, LB-100. This initiative aims to enhance cancer treatment efficacy by identifying promising drug pairings and understanding the underlying molecular mechanisms. Pre-clinical studies, led by noted researcher Professor René Bernards, will utilize innovative genetic techniques to select effective drug combinations, potentially improving outcomes for patients.